Derazantinib and Atezolizumab in Patients With Urothelial Cancer
Status:
Recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate efficacy of derazantinib monotherapy or
derazantinib-atezolizumab in combination in patients with advanced urothelial cancer
harboring fibroblast growth factor receptor (FGFR) genetic aberrations (GA) of various
clinical stages of disease progression and prior treatments.